• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Histological grade predicts for recurrence in patients with uterine endometrioid carcinoma without myometrial involvement
【24h】

Histological grade predicts for recurrence in patients with uterine endometrioid carcinoma without myometrial involvement

机译：组织学分级可预测无子宫肌层受累的子宫内膜样癌患者的复发

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To evaluate clinical outcomes and identify factors predictive for recurrence in patients with 1988 (FIGO) stage IA uterine endometrioid carcinoma. Patients and Methods: Patients who underwent hysterectomy for stage IA carcinoma were identified in our database. Fisher's exact and χ 2 tests were used to identify factors that influenced outcome. Survival plots were generated according to Kaplan-Meier product-limit method and the log-rank test was used to determine significance. Results: A total of 121 patients were identified. Eighty-seven percent (n=105) had tumor FIGO grade 1, 9% (n=11) grade 2, and 4% (n=5) grade 3 tumors. Six patients (5%) experienced recurrence. The 5-year recurrence-free survival (RFS), disease-specific survival (DSS) and overall survival (OS) were 93%, 95%, and 85%, respectively. On univariate analysis, tumor FIGO grade 2/3 was strongly associated with tumor recurrence (p=0.003), DSS (p=0.016), and OS (p=0.023). The 5-year RFS, DSS, and OS were 65.1%, 73.9%, and 63.9% respectively for patients with grade 2 and 3 tumors, which were significantly less than the corresponding rates of 97.5% (p≤0.0001), 98.6% (p=0.001), and 87.7% (p=0.024) for patients with grade 1 tumors. Conclusion: In this large cohort of patients, RFS, DSS and OS were excellent. Patients with FIGO grade 2/3 tumors had worse outcomes compared to those with grade 1 tumors. Therefore, while most patients with stage IA disease do not need adjuvant treatment after hysterectomy, our results suggest that patients with higher-grade tumors have an increased likelihood for recurrence and they may benefit from counseling regarding adjuvant therapies.
机译：目的：评估1988年（FIGO）IA期子宫内膜样癌患者的临床结局并确定可预测复发的因素。患者和方法：在我们的数据库中确定了因IA期癌而接受子宫切除术的患者。 Fisher精确检验和χ2检验用于确定影响结果的因素。根据Kaplan-Meier乘积极限法生成生存图，并使用对数秩检验确定显着性。结果：共鉴定出121例患者。 87％（n = 105）患有FIGO 1级，9％（n = 11）2级和4％（n = 5）3级肿瘤。六名患者（5％）经历了复发。 5年无复发生存期（RFS），疾病特异性生存期（DSS）和总体生存期（OS）分别为93％，95％和85％。单因素分析显示，FIGO 2/3级肿瘤与肿瘤复发（p = 0.003），DSS（p = 0.016）和OS（p = 0.023）密切相关。 2级和3级肿瘤患者的5年RFS，DSS和OS分别为65.1％，73.9％和63.9％，显着低于相应比率的97.5％（p≤0.0001），98.6％（ p = 0.001）和17.7级肿瘤患者的87.7％（p = 0.024）。结论：在这一大群患者中，RFS，DSS和OS表现出色。与患有1级肿瘤的患者相比，患有FIGO 2/3级肿瘤的患者的预后较差。因此，尽管大多数IA期疾病患者在子宫切除后不需要辅助治疗，但我们的结果表明，具有较高级别肿瘤的患者复发的可能性更高，他们可能会从辅助治疗咨询中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号